ArriVent Announces Positive Phase 1b Data For Firmonertinib In NSCLC With EGFR PACC Mutations
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – ArriVent BioPharma Inc. (AVBP) announced positive proof-of-concept randomized global Phase 1b FURTHER interim data for first-line firmonertinib monotherapy in patients with non-small cell lung cancer or NSCLC harboring EGFR PACC mutations.
:max_bytes(150000):strip_icc():format(jpeg)/PropertyValuation-4ecdfe3a87144fe998087ef433f49c13.jpeg "Is There a Gender Gap in Home Equity Loans?")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1346781100-2724c28da6b2479b88db9d1337ebe926.jpg "Buy Now, Pay Later or Rent-to-Own: Which Is the Smarter Way to Pay for Purchases?")